PNH - Paroxysmal Nocturnal Hemoglobinuria
Hematology·MeSH: Hemoglobinuria, Paroxysmal
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| xh-s003 | RA PHARMACEUTICALS, INC. (RARX) |
Frequently asked questions
How many drugs are in development for PNH - Paroxysmal Nocturnal Hemoglobinuria?
BioSniper tracks 1 drug in development for PNH - Paroxysmal Nocturnal Hemoglobinuria across 1 company.
How many clinical trials target PNH - Paroxysmal Nocturnal Hemoglobinuria?
There are 1 clinical trial targeting PNH - Paroxysmal Nocturnal Hemoglobinuria tracked by BioSniper.
What is the prevalence of PNH - Paroxysmal Nocturnal Hemoglobinuria?
The estimated prevalence of PNH - Paroxysmal Nocturnal Hemoglobinuria is approximately 5.0 per 100,000 population.
Deep-dive into PNH - Paroxysmal Nocturnal Hemoglobinuria
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis